|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Diazoxide#Use in Specific Populations]] |
| {{Diazoxide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Use in Specific Populations==
| |
| | |
| ===Pregnancy Category C===
| |
| | |
| Reproduction studies using the oral preparation in rats have revealed increased fetal resorptions and delayed parturition, as well as fetal skeletal anomalies; evidence of skeletal and cardiac teratogenic effects in rabbits has been noted with intravenous administration. The drug has also been demonstrated to cross the placental barrier in animals and to cause degeneration of the fetal pancreatic beta cells (See ANIMAL PHARMACOLOGY AND/OR TOXICOLOGY). Since there are no adequate data on fetal effects of this drug when given to pregnant women, safety in pregnancy has not been established. When the use of PROGLYCEM® is considered, the indications should be limited to those specified above for adults (See INDICATIONS AND USAGE), and the potential benefits to the mother must be weighed against possible harmful effects to the fetus.
| |
| | |
| ===Non-teratogenic effects===
| |
| | |
| Diazoxide crosses the placental barrier and appears in cord blood. When given to the mother prior to delivery of the infant, the drug may produce fetal or neonatal [[hyperbilirubinemia]], [[thrombocytopenia]], altered carbohydrate metabolism, and possibly other side effects that have occurred in adults.
| |
| | |
| [[Alopecia]] and [[hypertrichosis]] lanuginosa have occurred in infants whose mothers received oral diazoxide during the last 19 to 60 days of pregnancy.
| |
| | |
| ===Labor and delivery===
| |
| | |
| Since intravenous administration of the drug during labor may cause cessation of uterine contractions, and administration of oxytocic agents may be required to reinstate labor, caution is advised in administering PROGLYCEM® at that time.
| |
| | |
| ===Nursing mothers===
| |
| | |
| Information is not available concerning the passage of diazoxide in breast milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions from diazoxide in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
| |
| | |
| ===Pediatric use===
| |
| | |
| (See INDICATIONS AND USAGE).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b16c7832-2fd9-49af-b923-1dc0d91fd6e2 | publisher = | date = | accessdate = 26 February 2014 }}</ref>
| |
| ==References==
| |
| {{reflist|2}}
| |
| | |
| {{Nonsympatholytic vasodilatory antihypertensives}}
| |
| {{Other therapeutic products}}
| |
| {{Channel openers}}
| |
| | |
| [[Category:Sulfonamides]]
| |
| [[Category:Vasodilators]]
| |
| [[Category:Potassium channel openers]]
| |
| [[Category:Benzothiadiazines]]
| |
| [[Category:Organochlorides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |